Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00113646 · ClinicalTrials.gov registry record · Phase 2
Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT00113646: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00113646 is a Phase 2 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00113646, a Phase 2 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if recipients of non-myeloablative ex-vivo T-cell depleted peripheral blood (PBSC) stem cell transplantation using a mismatched related donor will have less severe graft versus host disease (GVHD), transplant related mortality, and less graft failure compared to alternative haploidentical stem cell transplantation.
Interventions
- DRUG MEDI-507
- PROCEDURE Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2002-11 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00113646
The ClinicalTrials.gov registry entry for NCT00113646 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MEDI-507 is the first listed.
NCT00113646 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00113646 about?
NCT00113646 is a clinical study titled "Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies". The purpose of this study is to determine if recipients of non-myeloablative ex-vivo T-cell depleted peripheral blood (PBSC) stem cell transplantation using a mismatched related donor will have less severe graft versus host disease (GVHD), transplant related mortality, and less graft failure compare...
What is the current status of trial NCT00113646?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2002-11. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00113646?
The interventions under investigation include: MEDI-507 (DRUG), Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00113646?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.